Sarepta Therapeutics and Jerry R. Mendell, M.D. from Nationwide Children’s Hospital to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program from the 23rd International Annual Congress of the World Muscle Society
CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, and Jerry R. Mendell, M.D., Curran-Peters Chair of Pediatric Research and Professor of Pediatrics and Neurology, Nationwide Children’s Hospital and The Ohio State University; The Research Institute at Nationwide Children’s Hospital, will host a webcast conference call from the 23rd International Annual Congress of the World Muscle Society (WMS) in Mendoza, Argentina, on Thursday, October 4, 2018 at 7:00 a.m. Eastern Time / 8:00 a.m. local Argentina time. The call will focus on an update regarding Sarepta’s Duchenne muscular dystrophy (DMD) micro-dystrophin gene therapy program and will be led by Dr. Mendell, a renowned researcher in the field of DMD.
The event will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com. Please connect to the webcast several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary, as slides will be included in the presentation. A conference call will also be provided for those who opt to listen to the event by telephone. The listen-only mode conference call can be accessed by dialing 844-534-7313 for domestic callers and +1-574-990-1451 for international callers. The passcode for the call is 5979938. Please specify to the operator that you would like to join the “Sarepta Update Call.” An archived webcast will be available on Sarepta’s website for 90 days following the event.
About Sarepta TherapeuticsSarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates. For more information, please visit: www.sarepta.com.
Internet Posting of InformationWe routinely post information that may be important to investors in the ‘For Investors’ section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.